undamentalytics Newsletter
Sign in

Biofrontera Inc. revenue

Biofrontera Inc.'s revenue was $41.7m in fiscal 2025, up 11.7% on the year before. Since fiscal 2020 ($18.8m) it has grown at a compound 17.2% a year. Over the last twelve months it was $46.2m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue19242934374246
Growth on the year before—+27.9%+19.0%+18.8%+9.5%+11.7%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Biofrontera Inc. $46.2m 17.8% 16.7%
Cumberland Pharmaceuticals Inc $39.9m -5.2% -0.6%
Aquestive Therapeutics, Inc. $54.1m 22.6% 5.2%
IM Cannabis Corp. $39.2m -0.7% —
BGM Group Ltd. $37.9m 51.1% —
Aytu Biopharma, Inc $57.6m -13.3% -18.8%

Compare with peers

Head to head: BFRI vs CPIXAQST vs BFRIBFRI vs IMCC

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Biofrontera Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Biofrontera Inc.